Novobiocin
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Novobiocin
Description:
Novobiocin (Albamycin) is a potent and orally active antibiotic. Novobiocin also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin shows anti-orthopoxvirus activity[1][2][3][4][6].Product Name Alternative:
Albamycin; CathomycinUNSPSC:
12352005Hazard Statement:
H302, H312, H332Target:
Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; HSP; OrthopoxvirusType:
Natural ProductsRelated Pathways:
Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/ProteaseApplications:
COVID-19-anti-virusField of Research:
Cancer; InfectionAssay Protocol:
https://www.medchemexpress.com/novobiocin.htmlConcentration:
10mMPurity:
97.88Solubility:
DMSO : 100 mg/mL (ultrasonic)Smiles:
CC1=C(O2)C(C(O)=C(NC(C3=CC(C/C=C(C)/C)=C(O)C=C3)=O)C2=O)=CC=C1O[C@H]4[C@@H]([C@@H]([C@@H](OC)C(C)(C)O4)OC(N)=O)OMolecular Formula:
C31H36N2O11Molecular Weight:
612.62Precautions:
H302, H312, H332References & Citations:
[1]Marcu MG, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000 Nov 24;275 (47) :37181-6.|[2]Ali-Osman F, et al. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res. 1993 Dec 1;53 (23) :5663-8.|[3]RodrÃguez-Cerrato V, et al. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci. Int J Antimicrob Agents. 2010 Jun;35 (6) :544-9.|[4]Eder JP, et al. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991 Jan 15;51 (2) :510-3. |[5]Bhatia S, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.Blood. 2018 Jul 19;132 (3) :307-320.|[6]Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19 (3) :115-24. |[7]Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19 (3) :115-24.Shipping Conditions:
Blue IceStorage Conditions:
-20°C (Powder, sealed storage, away from moisture)Scientific Category:
Natural ProductsClinical Information:
LaunchedIsoform:
HSP90; β-lactamCitation 01:
BioRxiv. 2025 Sep 15.|J Med Virol. 2025 Oct;97 (10) :e70655.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Nat Methods. 2023 Sep;20 (9) :1388-1399.|Adv Sci (Weinh) . 2022 Dec;9 (34) :e2203088.|Blood. 2018 Jul 19;132 (3) :307-320.|Cancer Res Commun. 2024 Apr 9;4 (4) :1024-1040.|Cell Rep Med. 2024 May 29:101592.|Int J Mol Sci. 2019 Mar 5;20 (5) . pii: E1125. |J Med Virol. 2025 Oct;97 (10) :e70655.|Surgery. 2024 Jun 18:S0039-6060 (24) 00303-9.CAS Number:
[303-81-1]
